ARNA Related Major News
-
Arena (ARNA) Confirms BELVIQ Will Soon Be Available for Sale in the U.S.
-
Arena Pharmaceuticals, Inc. (ARNA) Misses Q1 EPS by 2c
-
Arena Pharmaceuticals (ARNA) Withdraws EU BELVIQ Application
-
UPDATE: Arena Pharmaceuticals (ARNA) Narrows Q4 GAAP Loss to 10c/Share
-
Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of 7c/Share
-
Arena Pharmaceuticals, Inc. (ARNA) Posts Q2 Loss of 12c/Share, Wider than Views
-
Arena (ARNA) Confirms FDA Approval of BELVIQ
-
Arena Pharma (ARNA) Confirms FDA Panel Voted Benefits of Lorcaserin Outweigh Risks
-
Arena Pharmaceuticals, (ARNA) Posts Wider than Expected Q4 Loss of 16c/Share
-
Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of 16c/Sh.
-
Arena Pharmaceuticals, Inc. (ARNA) Reports In-Line Q2 Loss of 16c/Share
-
Arena Pharmaceuticals (ARNA) Posts Mixed Q1 Results
-
Arena Pharma (ARNA) Posts Narrower than Expected Q4 Loss
-
Arena Pharma (ARNA) Posts Q3 Loss of $0.31, Misses Views; Revs Heavy
-
Arena Pharma (ARNA) and Eisai Receive Complete Response for Lorcaserin NDA; FDA Cannot Approve Application in Present Form
-
Arena Pharmaceuticals (ARNA) Tops Q2 Loss Views by 1c
-
Arena Pharma (ARNA) Posts Q1 Loss of $0.33, Misses by 1c
-
Arena Pharma (ARNA) Posts Q4 Loss of $0.32, Misses by 1c
-
Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of $0.38, Misses by 4c
-
Arena Pharmaceuticals (ARNA) Reports a Q2 Loss; Comments on Outlook
-
Arena Pharmaceuticals (ARNA) Miss Q1 Revenue View
-
Arena Pharmaceuticals (ARNA) Misses Q4 View By 6c
-
Arena Pharmaceuticals (ARNA) Tops Q3 EPS by 7c, Updates Guidance
-
Arena Pharmaceuticals (ARNA) Reports Q2 Loss of $0.89
-
Arena Pharmaceuticals (ARNA) Reports Q1 Loss of $0.75, Misses By 8c
-
Arena Pharmaceuticals (ARNA) Reports Q4 Loss of $0.60
Back to ARNA Stock Lookup
